NASDAQ: SMMT

Summit Therapeutics (SMMT) Stock Analysis & Forecast

Nov 13 close

$14.15−0.93 (−6.2%)

Gekko Brief

AI summaryNov 9 close

Summit Therapeutics moved higher this week after third-quarter results showed a narrower net loss of $208.4 million, or adjusted loss per share of $(0.20), beating analyst estimates of $(0.28). The quarter also featured a nine-month net loss of $613.5 million, shareholder approval to raise authorized common stock to 2 billion shares, and confirmation that AstraZeneca invested $2 billion in the company. Stifel lowered its price target to $37 from $38 while maintaining a Buy rating, citing valuation concerns even as it highlighted promising ivonescimab data and accelerated enrollment in colorectal cancer trials.

Shares closed at $17.84, up 9.2% on the day, sitting above both the 50-day ($16.33) and 200-day ($16.15) moving averages, with the shorter average above the longer one. The GekkoIndex reads 52.5, placing SMMT in the Neutral zone, down 7.9 over the past five readings. Price remains 11.1% below Gekko Fair Value of $20.06.

The next earnings date falls on 22 February 2027, 99 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, though one trailblazer holder is noted. Seasonality from this point in the calendar has averaged a 25.6% move over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus among 14 firms stands at 8 buy and 6 hold ratings, with a consensus target of $30.26.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Summit Therapeutics price vs fair value

$19.63$14.15Nov ’25May ’26Nov ’26
Close $14.15200-day averageGekko Fair Value $19.63

Summit Therapeutics quick facts

Market cap
$11.29B
P/E ratio
—
Forward P/E
3.7
EPS, TTM
−$1.06
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
-1.52
Volume
5.48M avg 4.82M
1-year return
−24.9%
Typical daily move
±9.4%
Typical 20-day move
±14.5%
50-day average
$16.41
200-day average
$16.15
Next earnings
Feb 22
Shares outstanding
799.8M
52-week range
$12.07$29.23

Summit Therapeutics swing-trade checklist

Summit Therapeutics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $14.15 sits between the 50-day ($16.41) and 200-day ($16.15) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    61.7, Accumulation

    Reading 61.7 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    27.9% below

    Price is 27.9% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 99 days

    Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +53.7% on average

    From this point in the calendar, the next 20 trading days averaged +53.7% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Summit Therapeutics stock chart and price history

Summit Therapeutics closed at $14.15 on Nov 13, 2026, −24.9% over the past year, inside a 52-week range of $12.07 to $29.23.

Close50-day average200-day averageVolume
Summit Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$20$25DecJan 2026FebMarAprMayJunJulAugSepOctNov14.15

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−7.9%
3 months
+10.7%
6 months
−16.1%
1 year
−24.9%
The full SMMT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SMMT in Gekko

Follow Summit Therapeutics through every session

Put SMMT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track SMMT in GekkoFree for 7 days. No credit card required.

About Summit Therapeutics

Summit Therapeutics works in biopharmaceutical research, focused on finding, developing, and bringing to market treatments for infectious diseases in the United States and Latin America. Much of its pipeline centers on Clostridioides difficile infection, or CDI, with an oral small-molecule antibiotic called ridinilazole as its most advanced candidate, now in Phase III trials for that condition.

Alongside ridinilazole, the company is advancing SMT-738, aimed at multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and a group of compounds known as DDS-04, which target various infections caused by Enterobacteriaceae bacteria. Its work is organized around this pipeline of infectious-disease therapies rather than a marketed product line.

Summit Therapeutics was founded in 2003 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker SMMT.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
smmttx.com

Summit Therapeutics GekkoIndex: the smart money zone

Summit Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.7, in the Accumulation zone, up 4 points over five sessions.

010061.7Accumulation

Up 4 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying19+25.7%+29.9%+36.3%+34.2%
Accumulation (current zone)242+2.7%+3.8%+5.9%+18.3%
Neutral410+1.7%+4.3%+8.1%+21.8%
Distribution27−4.9%−11.6%−12.9%−18.0%
Selling4Too few readings yet

Average SMMT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the SMMT price, zone by zone.Track SMMT in Gekko

Is Summit Therapeutics stock overvalued? Gekko Fair Value

Summit Therapeutics trades 27.9% below Gekko Fair Value of $19.63, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Summit Therapeutics shares are worth, recalculated every trading day.

$19.63

Gekko Fair Value, Nov 14, 2026

27.9% Undervalued

At the end of Aug 2026 the price was 41.9% below the estimate.

Gekko Fair ValueShare price, month end
$20$14Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open SMMT in Gekko

Summit Therapeutics insider and Congress trading

No open-market insider purchases were filed for Summit Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for SMMT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every SMMT insider filing, plotted on the chart in Gekko.Open SMMT in Gekko

Congress trades last 90 days

No trades in SMMT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for SMMT, plotted on the chart in Gekko.Open SMMT in Gekko

Unusual options activity last 30 days

1signal, 64% of the flagged premium in calls.

Latest: Bullish flow on Nov 14, $746K in unusual premium.

Hedge funds and billionaires quarter ended Mar 31

1of the funds Gekko tracks holds SMMT.

1added0opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Summit Therapeutics earnings: next date and track record

Summit Therapeutics reports on Feb 22, 2027 (99 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±12.6%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−14.8%Oct ’24−18.1%Feb ’25+15.7%May ’25−10.4%Aug ’25−10.7%Oct ’25+1.1%Feb ’26−22.7%Apr ’26−7.3%Jul ’26

Last earnings call, Jul 23, 2026 AI summary

What they said
Summit Therapeutics reported Q2 2026 results highlighting ivonescimab's strong clinical momentum with 4 positive Phase III readouts, 2 China approvals, and a pending FDA BLA decision expected late 2026. Over 70,000 patients have been treated commercially in China. The company has 15 Phase III trials ongoing across multiple tumor types and 52 total clinical trials initiated with partner Akeso. An updated OS analysis for the HARMONi trial was recently announced.
Guidance
Summit anticipates an FDA BLA decision on ivonescimab towards end of 2026 and is actively preparing for commercialization. Management is expanding clinical development plans across multiple solid tumor indications while pursuing combination therapy partnerships with large pharma.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 23, 2026−$0.28
est −$0.26
−7.7%—
est $114K
—−7.3%
Apr 30, 2026−$0.18
est −$0.12
−45.2%—
est $54K
—−22.7%
Feb 23, 2026−$0.29
est −$0.10
−182.5%—
est $56.78M
—+1.1%
Oct 20, 2025−$0.23
est −$0.10
−124.3%—
est $76.50M
—−10.7%
Aug 11, 2025−$0.76
est −$0.09
−736.9%——−10.4%
May 1, 2025−$0.07
est −$0.07
+0.7%——+15.7%
Feb 24, 2025−$0.07
est −$0.08
+12.5%——−18.1%
Oct 30, 2024−$0.08
est −$0.07
−14.3%——−14.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Summit Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Summit Therapeutics is $29.49, +108.4% from the last close, from 14 firms rating the stock in the last 90 days.

$29.49consensus 12-month target, +108.4% from the last close
Low $11.90High $43
Buy8
Hold6
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11Wells FargoBuy, maintained$30+112.0%
Nov 9BernsteinHold, reiterated$11.90−15.9%
Nov 5Evercore ISIBuy, maintained$34+140.3%
Nov 5H.C. WainwrightHold, reiterated——
Nov 5Stifel NicolausBuy, maintained$37+161.5%
+5.9%average 20-day move after past Accumulation readings
+53.7%average move over the next 20 trading days in the last 5 years
±9.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Summit Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Summit Therapeutics averaged +53.7% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−11.0%2021+272.4%2022+18.8%2023−8.3%2024−3.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−6.0%1 of 5
Next 10 trading days−5.1%0 of 5
Next 15 trading days+27.5%4 of 5
Next 20 trading days+53.7%2 of 5
Next 30 trading days+68.9%2 of 5

For scale, SMMT’s typical 20-trading-day move in either direction is about 14.5%.

Summit Therapeutics market cap and key statistics

Summit Therapeutics’s market cap is $11.29B and revenue of $0 over the last twelve months.

Valuation

Market cap
$11.29B
Forward P/E
3.7
EPS, TTM
−$1.06
Gekko Fair Value
$19.63

Trading

Volume
5.48M
Avg volume, 20 days
4.82M
52-week high
$29.23
52-week low
$12.07
Shares outstanding
799.8M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-220%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
-1.52
Typical daily move
±9.4%
Typical 20-day move
±14.5%

Summit Therapeutics stock news this week

Coverage of Summit Therapeutics this week reads negative: 0 positive, 1 neutral and 3 negative headlines.

News sentiment negative

Summit Therapeutics peers

Summit Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Summit Therapeutics stock FAQ

What is Summit Therapeutics’s market cap?

Summit Therapeutics’s market cap is $11.29B at the Nov 13, 2026 close of $14.15, with 799.8M shares outstanding.

What is the Summit Therapeutics stock forecast?

The consensus analyst 12-month price target for Summit Therapeutics is $29.49, +108.4% from the last close. Of the 14 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Summit Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Summit Therapeutics is undervalued: the Nov 13, 2026 close of $14.15 is 27.9% below Gekko Fair Value of $19.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Summit Therapeutics report earnings next?

Summit Therapeutics is expected to report on Feb 22, 2027 (99 days away). Analysts expect earnings of −$0.36 per share on revenue of $3.01M. Summit Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 12.6% on average across the report.

What is Summit Therapeutics’s 52-week high and low?

Summit Therapeutics’s 52-week high is $29.23 and its 52-week low is $12.07; it closed at $14.15 on Nov 13, 2026, −24.9% over the past year. Over the last five years the shares peaked at $36.91 on Apr 24, 2025.

Is Summit Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Summit Therapeutics?

Gekko flagged 1 unusual options signal in Summit Therapeutics over the last 30 days, with $477K of flagged premium in calls and $269K in puts. The latest, bullish flow, was on Nov 14, 2026 with $746K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Summit Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.